ParcelBio Emerges from Stealth with $13M to Advance Durable mRNA Platform for Chronic Diseases
核心洞察
ParcelBio (搜索) raised $13 million in seed financing led by Breyer Capital (搜索) to develop its APEXm (搜索)™ platform that enables significantly higher and more durable mRNA (搜索) protein expression compared to current technologies.
The company's proprietary platform engineers RNA molecules to recruit cellular RNA-stabilizing machinery (搜索), overcoming the transient expression limitations that have restricted mRNA (搜索) applications beyond vaccines.
ParcelBio (搜索)'s lead program focuses on in vivo CAR-T (搜索) therapies for autoimmune diseases, aiming to achieve deep B-cell depletion for durable remission without viral delivery or ex vivo manufacturing.
ParcelBio (搜索) has emerged from stealth mode with $13 million in seed financing to advance its next-generation mRNA (搜索) platform designed to overcome the durability limitations that have constrained RNA therapeutics beyond vaccine applications. The financing round was led by Breyer Capital (搜索), with participation from General Catalyst (搜索), Y Combinator (搜索), Metaplanet, SurgePoint Capital, ZAKA VC, and other investors.
The biotechnology company is developing what it calls a new class of potent and durable mRNA (搜索) medicines through its proprietary APEXm (搜索)™ (Amplified and Prolonged EXpression mRNA) platform. Unlike current mRNA technologies that typically result in short-lived protein expression, ParcelBio (搜索)'s approach engineers RNA molecules to actively recruit the cell's native RNA-stabilizing machinery (搜索).
Addressing the Durability Challenge
Current mRNA (搜索) technologies face fundamental limitations in achieving both high protein expression and sustained durability, often requiring tradeoffs between potency, duration, and manufacturability. These constraints have restricted broader mRNA applications beyond vaccines and short-acting therapeutics.
"mRNA (搜索) has transformed medicine, but today's technologies are fundamentally limited in how much protein they can produce and for how long," said Dr. David Weinberg, CEO and Co-Founder of ParcelBio (搜索). "We engineered RNA to work with the cell's machinery rather than against it, enabling meaningful improvements in both expression and durability that we believe are essential for true disease modification."
The APEXm (搜索)™ platform maintains a simple, linear mRNA (搜索) architecture while delivering both high peak expression and sustained activity. Unlike circular RNA and other next-generation approaches that often introduce manufacturing complexity or reduce peak output, ParcelBio (搜索)'s technology is designed to be modular and broadly applicable across proteins and cell types.
Lead Program Targets Autoimmune Diseases
ParcelBio (搜索)'s lead program focuses on in vivo CAR-T (搜索) therapies targeting pathogenic B cells (搜索) across autoimmune diseases. The goal is to achieve deep B-cell depletion for durable, drug-free remission by enabling sustained CAR expression without viral delivery or ex vivo manufacturing. This approach aims to develop scalable, off-the-shelf therapies with curative potential.
"ParcelBio (搜索)'s durable, tunable expression is designed to collapse the tradeoffs that have constrained mRNA (搜索) in chronic, deep-tissue disease, bringing durable, controllable immune reset within reach in refractory autoimmunity and beyond," said Dr. Morgan Cheatham, Partner and Head of Healthcare and Life Sciences at Breyer Capital (搜索).
Preclinical Validation and Pipeline Expansion
Preclinical data demonstrate that ParcelBio (搜索)'s APEXm (搜索)™ RNA drives significantly higher and more durable protein expression compared to a leading clinical mRNA (搜索) design. This enhanced performance translates into deeper biological responses, including more complete target cell depletion in in vivo CAR-T (搜索) models.
The company plans to debut the APEXm (搜索)™ platform and preclinical data in an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting on May 14, 2026. Beyond autoimmune applications, ParcelBio (搜索) is developing additional programs in oncology (搜索) and encoded protein therapeutics.
"Most RNA platforms force a tradeoff between potency, durability, and manufacturability," said Dr. Chris Carlson, Chief Scientific Officer and Co-Founder of ParcelBio (搜索). "Our approach eliminates that tradeoff, enabling both higher peak expression and longer duration within a manufacturable system, and opening the door to entirely new classes of medicines."
Platform Technology for Chronic Disease Management
The financing will support development of the APEXm (搜索)™ platform and advance ParcelBio (搜索)'s pipeline across multiple therapeutic areas. The platform's ability to achieve sustained protein production addresses a critical bottleneck that has limited mRNA (搜索)'s application in chronic diseases requiring long-term biological effects.
For conditions characterized by chronic inflammation, immune dysfunction, or progressive tissue damage, transient bursts of protein production may not provide sufficient therapeutic benefit. ParcelBio (搜索)'s approach represents a shift from episodic intervention toward programmable, sustained biological modulation suitable for chronic disease (搜索) management.